Management of Aromatase Inhibitor–Induced Musculoskeletal Symptoms

2020 ◽  
Vol 16 (11) ◽  
pp. 733-739 ◽  
Author(s):  
Arjun Gupta ◽  
N. Lynn Henry ◽  
Charles L. Loprinzi
Keyword(s):  
Quality Of Life ◽  
Aromatase Inhibitor ◽  
Inhibitor Therapy ◽  
Musculoskeletal Symptoms ◽  
Evidence Based ◽  
Distinct Entity ◽  
Aromatase Inhibitor Therapy ◽  
Prevention And Treatment

Aromatase inhibitor–induced musculoskeletal symptoms (AIMSS) were first recognized as a distinct entity in 2001, 5 years after the approval of the first aromatase inhibitor, anastrozole. Musculoskeletal symptoms can severely affect patients’ quality of life and also lead to premature discontinuation of aromatase inhibitor therapy. Several interventions for managing AIMSS have been investigated in the last decade, with some demonstrating promise. This article provides an evidence-based summary to guide practicing oncologists in regard to the epidemiology, prevention, and treatment of AIMSS.

Androgens and musculoskeletal symptoms among breast cancer patients on aromatase inhibitor therapy

2011 ◽  
Vol 130 (2) ◽  
pp. 569-577 ◽  
Author(s):  
Lisa Gallicchio ◽  
Ryan MacDonald ◽  
Bethany Wood ◽  
Errol Rushovich ◽  
Kathy J. Helzlsouer
Keyword(s):  
Breast Cancer ◽  
Aromatase Inhibitor ◽  
Cancer Patients ◽  
Inhibitor Therapy ◽  
Musculoskeletal Symptoms ◽  
Breast Cancer Patients ◽  
Aromatase Inhibitor Therapy

scholarly journals Physical Exercise with or without Whole-Body Vibration in Breast Cancer Patients Suffering from Aromatase Inhibitor—Induced Musculoskeletal Symptoms: A Pilot Randomized Clinical Study

2021 ◽  
Vol 11 (12) ◽  
pp. 1369
Author(s):  
Alessandro de Sire ◽  
Lorenzo Lippi ◽  
Antonio Ammendolia ◽  
Carlo Cisari ◽  
Konstantinos Venetis ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Quality Of Life ◽  
Muscle Strength ◽  
Physical Exercise ◽  
Aromatase Inhibitor ◽  
Physical Performance ◽  
Whole Body Vibration ◽  
Musculoskeletal Symptoms ◽  
Whole Body

In this study, we aimed to assess the safety and efficacy of physical exercise, with or without whole-body vibration (WBV), in patients with aromatase inhibitor-induced musculoskeletal symptoms (AIMSS). Eligible patients were adults (≥18 years) with a history of breast cancer and current AIMSS. Enrolled patients (n = 22) were randomly assigned 1:1 to receive physical exercise combined with WBV or sham WBV for 4 weeks. The primary endpoint was pain intensity measured by numerical pain rating scale (NPRS). The secondary endpoints were muscle strength, physical function, physical performance, and quality of life. The WBV group (mean age: 51.73 ± 10.73 years; body mass index (BMI): 25.56 ± 5.17 kg/m2) showed a statistically significant pain reduction (NPRS: 6.82 ± 1.17 vs. 5.73 ± 1.01; p = 0.031), whereas patients in the sham WBV group (mean age: 58.55 ± 9.71 years; BMI: 27.31 ± 3.84 kg/m2), did not reach statistical significance (NPRS: 6.91 ± 2.02 vs. 5.91 ± 2.51; p = 0.07). Concurrently, muscle strength, physical performance, and quality of life significantly improved in both groups, without significant differences between groups. No dropouts and no side effects were recorded. Both patients and the physical therapist reported a high level of satisfaction with the intervention. Our findings suggest that physical exercise and WBV combination might be a safe therapeutic option for improving the rehabilitative management of patients with AIMSS.

Sign in / Sign up

Export Citation Format

Share Document